Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.

Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. J Virol (2002) 2.50

Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci U S A (2000) 2.23

The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci U S A (2001) 1.94

Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol (2002) 1.67

Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J Virol (2001) 1.57

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J Virol (2005) 1.52

Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol (2000) 1.47

Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J Virol (2002) 1.44

Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci U S A (2000) 1.42

Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J Virol (2001) 1.37

A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol (2007) 1.36

Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol (2005) 1.36

Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci U S A (1999) 1.32

Nanoparticles in modern medicine: state of the art and future challenges. Int J Nanomedicine (2007) 1.28

Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J Virol (2008) 1.27

Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J Virol (2001) 1.18

What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? Retrovirology (2009) 1.15

Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One (2010) 1.13

Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clin Microbiol Rev (2002) 1.12

Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J Virol (2006) 1.11

Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J Virol (2003) 1.06

Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection. Vaccine (2008) 1.05

Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization. J Virol (2004) 1.05

HIV-1 Tat promotes Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6-induced angiogenesis and tumorigenesis by regulating PI3K/PTEN/AKT/GSK-3β signaling pathway. PLoS One (2013) 1.05

Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein. J Virol (2002) 1.03

Novel biopanning strategy to identify epitopes associated with vaccine protection. J Virol (2013) 1.01

Distribution, persistence, and efficacy of adoptively transferred central and effector memory-derived autologous simian immunodeficiency virus-specific CD8+ T cell clones in rhesus macaques during acute infection. J Immunol (2009) 1.00

Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin Biol Ther (2008) 1.00

Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection. J Virol (2004) 0.98

Tat-neutralizing antibodies in vaccinated macaques. J Virol (2003) 0.94

Is an HIV vaccine possible? Nat Med (1999) 0.93

Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy. J Virol (2000) 0.93

Challenges in HIV Vaccine Research for Treatment and Prevention. Front Immunol (2014) 0.93

HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies. PLoS One (2012) 0.91

Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine. Retrovirology (2006) 0.90

Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis. J Virol (2005) 0.90

Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene. Am J Pathol (2000) 0.89

HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology (2015) 0.89

Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination. J Virol (2004) 0.89

Proliferative activity of extracellular HIV-1 Tat protein in human epithelial cells: expression profile of pathogenetically relevant genes. BMC Microbiol (2005) 0.88

Modulation of dendritic cell maturation and function by the Tax protein of human T cell leukemia virus type 1. J Leukoc Biol (2007) 0.88

Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P. J Virol (2010) 0.88

Using death to one's advantage: HIV modulation of apoptosis. Leukemia (2001) 0.86

A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice. Proc Natl Acad Sci U S A (2002) 0.84

AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens. J Virol (2006) 0.83

Differences in time of virus appearance in the blood and virus-specific immune responses in intravenous and intrarectal primary SIVmac251 infection of rhesus macaques; a pilot study. BMC Infect Dis (2001) 0.83

The infiltration kinetics of simian immunodeficiency virus-specific T cells drawn to sites of high antigenic stimulation determines local in vivo viral escape. Proc Natl Acad Sci U S A (2001) 0.83

Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication. Proc Natl Acad Sci U S A (2000) 0.83

Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein. J Virol (2004) 0.82

MiRNA-891a-5p mediates HIV-1 Tat and KSHV Orf-K1 synergistic induction of angiogenesis by activating NF-κB signaling. Nucleic Acids Res (2015) 0.79

Macaque-tropic human immunodeficiency virus type 1: breaking out of the host restriction factors. Front Microbiol (2013) 0.79

The grafting of universal T-helper epitopes enhances immunogenicity of HIV-1 Tat concurrently improving its safety profile. PLoS One (2014) 0.77

A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice. Sci Rep (2016) 0.76

HIV Tat-mediated transcriptional regulation of proteasome protein cleavage specificity. Biochem J (2006) 0.76

Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV). Plant Cell Rep (2011) 0.76

Induction of antibodies and T cell responses by a recombinant influenza virus carrying an HIV-1 TatΔ51-59 protein in mice. Biomed Res Int (2014) 0.75

IL-7 receptor recovery on CD8 T-cells isolated from HIV+ patients is inhibited by the HIV Tat protein. PLoS One (2014) 0.75

Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide. Hum Vaccin Immunother (2015) 0.75

HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology. BMC Infect Dis (2016) 0.75

Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines. PLoS One (2014) 0.75

Single nucleotide polymorphisms in the FcγR3A and TAP1 genes impact ADCC in cynomolgus monkey PBMCs. Immunogenetics (2017) 0.75

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (1996) 11.37

The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16

Oncogenic response of rat skin, lungs, and bones to vinyl chloride. Cancer Res (1971) 4.39

Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. Science (1990) 4.28

Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J (2010) 3.81

Biologically diverse molecular variants within a single HIV-1 isolate. Nature (1988) 3.80

LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J (2009) 3.16

Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8. J Virol (1997) 2.59

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J (2010) 2.56

Retrieved endogenous biotin: a novel marker and a potential pitfall in diagnostic immunohistochemistry. Histopathology (1997) 2.31

Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells. Science (1988) 2.30

Programmed cell death in AIDS-related HIV and SIV infections. AIDS Res Hum Retroviruses (1993) 2.29

Long term effect of alpha interferon in children with chronic hepatitis B. Gut (2000) 2.21

Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells. J Natl Cancer Inst (1999) 2.18

HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS (1997) 2.15

Production of cloned pigs from in vitro systems. Nat Biotechnol (2000) 2.15

Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. Blood (1999) 2.10

Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. Eur Respir J (2009) 2.07

Myopericarditis versus viral or idiopathic acute pericarditis. Heart (2007) 2.02

Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases. J Natl Cancer Inst (1999) 2.01

Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell (2000) 1.98

Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol (1992) 1.97

Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6. Nature (1989) 1.96

New human and simian HIV-related retroviruses possess functional transactivator (tat) gene. Nature (1987) 1.93

The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci U S A (1993) 1.93

Identification and culture of Kaposi's sarcoma-like spindle cells from the peripheral blood of human immunodeficiency virus-1-infected individuals and normal controls. Blood (1994) 1.93

Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol (2000) 1.92

Immune activation in africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS (2000) 1.91

Granzyme B is inhibited by the cowpox virus serpin cytokine response modifier A. J Biol Chem (1995) 1.88

A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J Virol (1998) 1.79

HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines. Proc Natl Acad Sci U S A (1996) 1.67

Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci U S A (1995) 1.64

Central nervous system involvement during infection by Phlebovirus toscana of residents in natural foci in central Italy (1977-1988). Am J Trop Med Hyg (1991) 1.62

Transcellular transactivation by the human immunodeficiency virus type 1 tat protein. J Virol (1991) 1.57

The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. EMBO J (2001) 1.53

Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells. J Clin Invest (1995) 1.43

Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis. J Immunol (1992) 1.42

Yellow palms with disulfiram. Lancet (1997) 1.39

Does HHV-8 have a protective role on the development of HIV encephalopathy? Italian HIV-Seroconversion Study. Neurology (1999) 1.38

Lack of chronic immune activation in HIV-infected chimpanzees correlates with the resistance of T cells to Fas/Apo-1 (CD95)-induced apoptosis and preservation of a T helper 1 phenotype. J Immunol (1997) 1.38

[Coronary angioplasty in an Italian hospital without on-site cardiac surgery: the results and outlook]. G Ital Cardiol (1994) 1.38

Retention magnets in guiding plates of distal-extension removable partial dentures. J Prosthet Dent (1988) 1.37

Estimating diagnostic accuracy of tests for latent tuberculosis infection without a gold standard among healthcare workers. Euro Surveill (2009) 1.35

Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro. Gene Expr (1992) 1.34

Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J Infect Dis (1997) 1.32

Overproduction of the free radical of ribonucleotide reductase in hydroxyurea-resistant mouse fibroblast 3T6 cells. Proc Natl Acad Sci U S A (1981) 1.31

HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine (1994) 1.31

Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J Gen Virol (1993) 1.31

Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection. J Infect Dis (1999) 1.30

Detection of interleukin-2 in addition to interferon-gamma discriminates active tuberculosis patients, latently infected individuals, and controls. Clin Microbiol Infect (2009) 1.29

Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res (1981) 1.29

Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol (1998) 1.28

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine (2001) 1.26

Active-site residues of cyclophilin A are crucial for its incorporation into human immunodeficiency virus type 1 virions. J Virol (1997) 1.25

The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood (1999) 1.25

Reference blood values of iron metabolism in cynomolgus macaques. Lab Anim Sci (1991) 1.23

gamma-Interferon produced by CD8+ T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: an immune response to human herpesvirus-8 infection? Blood (1998) 1.22

The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. Blood (1995) 1.21

A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization. J Virol (1990) 1.21

Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. Int J Tuberc Lung Dis (2008) 1.20

beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc Natl Acad Sci U S A (1998) 1.20

Osseointegration enhanced by chemical etching of the titanium surface. A torque removal study in the rabbit. Clin Oral Implants Res (1997) 1.19

Variability and evolution of Kaposi's sarcoma-associated herpesvirus in Europe and Africa. International Collaborative Group. AIDS (1999) 1.17

Antigenic and biological characterization of Toscana virus, a new Phlebotomus fever group virus isolated in Italy. Acta Virol (1984) 1.16

Vaccine protection against HIV-2 infection in cynomolgus monkeys. AIDS Res Hum Retroviruses (1991) 1.16

High seroprevalence of antibodies to human herpesvirus-8 in Egyptian children: evidence of nonsexual transmission. J Natl Cancer Inst (1999) 1.16

Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study. Clin Exp Immunol (2007) 1.16

Evolution of a simian immunodeficiency virus pathogen. J Virol (1998) 1.15

Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.15

Sandfly fever viruses in Italy. Arch Virol Suppl (1996) 1.14

Intestinal localization of anisakiasis manifested as acute abdomen. Clin Microbiol Infect (2003) 1.13

Carbohydrate determinant NeuAc-Gal beta (1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120. J Gen Virol (1992) 1.13

QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J (2008) 1.13

[Ecological and epidemiological studies of Toscana virus, an arbovirus isolated from Phlebotomus]. Ann Ist Super Sanita (1982) 1.12

Adenovirus type 12 early region 1A proteins repress class I HLA expression in transformed human cells. Proc Natl Acad Sci U S A (1986) 1.12

Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment. Virology (2001) 1.12

AIDS vaccine developments. Nature (1992) 1.11

Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: multicentre study with multiple and novel assays. J Med Virol (2001) 1.10

Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J Immunol (1999) 1.10

Early endosseous integration enhanced by dual acid etching of titanium: a torque removal study in the rabbit. Clin Oral Implants Res (2001) 1.10

The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure. J Virol (1994) 1.09

Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies. Immunology (1991) 1.09

Inflammatory cytokines induce endothelial cells to produce and release basic fibroblast growth factor and to promote Kaposi's sarcoma-like lesions in nude mice. J Immunol (1997) 1.09